Biofrontera AG nine-month (9M) EBITDA rises to EUR 1.8 million from a loss, global sales up 14.8 percent to EUR 12.3 million

Reuters11-28

<a href="https://laohu8.com/S/BFFTF">Biofrontera AG</a> nine-month (9M) EBITDA rises to EUR 1.8 million from a loss, global sales up 14.8 percent to EUR 12.3 million

Biofrontera AG reported group sales of EUR 12.3 million for the first nine months of 2025, marking an increase of 14.8 percent. EBITDA for the period reached EUR 1.8 million. EBIT rose to EUR 1.2 million. Sales to Biofrontera Inc. totaled EUR 3.1 million for the nine-month period. In the third quarter of 2025, sales to Biofrontera Inc. were EUR 0.6 million. Group sales in Europe increased by 7.5 percent in the first nine months of 2025. Distribution costs decreased to EUR 4.7 million. The financial result for the period was negative EUR 0.1 million. Net income after taxes for the first nine months of 2025 amounted to negative EUR 4.1 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera AG published the original content used to generate this news brief on November 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2586120740?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-28 17:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586120740","market":"nz","top_or_hot":-1,"title":"Biofrontera AG nine-month (9M) EBITDA rises to EUR 1.8 million from a loss, global sales up 14.8 percent to EUR 12.3 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BFFTF\">Biofrontera AG</a> nine-month (9M) EBITDA rises to EUR 1.8 million from a loss, global sales up 14.8 percent to EUR 12.3 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biofrontera AG reported group sales of EUR 12.3 million for the first nine months of 2025, marking an increase of 14.8 percent. EBITDA for the period reached EUR 1.8 million. EBIT rose to EUR 1.2 million. Sales to <a href=\"https://laohu8.com/S/BFRI\">Biofrontera Inc</a>. totaled EUR 3.1 million for the nine-month period. In the third quarter of 2025, sales to Biofrontera Inc. were EUR 0.6 million. Group sales in Europe increased by 7.5 percent in the first nine months of 2025. Distribution costs decreased to EUR 4.7 million. The financial result for the period was negative EUR 0.1 million. Net income after taxes for the first nine months of 2025 amounted to negative EUR 4.1 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera AG published the original content used to generate this news brief on November 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biofrontera AG nine-month (9M) EBITDA rises to EUR 1.8 million from a loss, global sales up 14.8 percent to EUR 12.3 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiofrontera AG nine-month (9M) EBITDA rises to EUR 1.8 million from a loss, global sales up 14.8 percent to EUR 12.3 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-28 17:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BFFTF\">Biofrontera AG</a> nine-month (9M) EBITDA rises to EUR 1.8 million from a loss, global sales up 14.8 percent to EUR 12.3 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biofrontera AG reported group sales of EUR 12.3 million for the first nine months of 2025, marking an increase of 14.8 percent. EBITDA for the period reached EUR 1.8 million. EBIT rose to EUR 1.2 million. Sales to <a href=\"https://laohu8.com/S/BFRI\">Biofrontera Inc</a>. totaled EUR 3.1 million for the nine-month period. In the third quarter of 2025, sales to Biofrontera Inc. were EUR 0.6 million. Group sales in Europe increased by 7.5 percent in the first nine months of 2025. Distribution costs decreased to EUR 4.7 million. The financial result for the period was negative EUR 0.1 million. Net income after taxes for the first nine months of 2025 amounted to negative EUR 4.1 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera AG published the original content used to generate this news brief on November 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL4bLjZY:1","article_id":"2586120740","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586120740","pubTimestamp":1764320528,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biofrontera AG reported group sales of EUR 12.3 million for the first nine months of 2025, marking an increase of 14.8 percent. EBITDA for the period reached EUR 1.8 million. EBIT rose to EUR 1.2 million. Sales to Biofrontera Inc. totaled EUR 3.1 million for the nine-month period. In the third quarter of 2025, sales to Biofrontera Inc. were EUR 0.6 million. Group sales in Europe increased by 7.5 percent in the first nine months of 2025. Distribution costs decreased to EUR 4.7 million. The financial result for the period was negative EUR 0.1 million. Net income after taxes for the first nine months of 2025 amounted to negative EUR 4.1 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera AG published the original content u","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BFRI":"Biofrontera Inc"},"translate_title":"Biofrontera AG九个月(900万)EBITDA从亏损增至180万欧元，全球销售额增长14.8%至1,230万欧元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BFRI":0.9},"content_text":"Biofrontera AG nine-month (9M) EBITDA rises to EUR 1.8 million from a loss, global sales up 14.8 percent to EUR 12.3 million\n    \n\n        Biofrontera AG reported group sales of EUR 12.3 million for the first nine months of 2025, marking an increase of 14.8 percent. EBITDA for the period reached EUR 1.8 million. EBIT rose to EUR 1.2 million. Sales to Biofrontera Inc. totaled EUR 3.1 million for the nine-month period. In the third quarter of 2025, sales to Biofrontera Inc. were EUR 0.6 million. Group sales in Europe increased by 7.5 percent in the first nine months of 2025. Distribution costs decreased to EUR 4.7 million. The financial result for the period was negative EUR 0.1 million. Net income after taxes for the first nine months of 2025 amounted to negative EUR 4.1 million.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera AG published the original content used to generate this news brief on November 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586120740","isCrawlerRequest":true}